This is a hard one Arnold ... I still believe that if there is ever an epidemic of fecal collation in the management, we have products either just entering the approval pipeline or prepared to enter when LW gets one of the big financing deals we have heard so much about over the past several years.
Unlike many, I still have great faith in the potential of a couple of the products ... herpes can be a very major revenue producer if the front office gang overcomes severe cases of rectal cranialitis and finds a way to get it to market. The many, many applications using the ICAM goo would bring PPS up into the $3 - 5 buck a pop range.
Unfortunately, I just don't think our front office gang can bring the works of the very blessed and brilliant back shop gang to the market. So, I suppose that will have to be set aside when making prognostications ... so here goes:
With current management:
SynDNA works ... $.15 - .60 a share
SynDNA doesn't work ... $.15 - .60 a share.
Well ... even SnyDNA will have to be marketed ... so, if we see the academics and penny stock peddlers give way to a first class bean counter and a vaccuum cleaner salesman that will change to:
SynDNA works ... $5.00 - $10.00 a share
Syndna doesn't work ... $.25- 1.00 per share